Story · Medicine & Biotech

Sellas’ cancer vaccine extends survival in blood cancer trial, company says

3 outlets · first reported by The Hindu Health on · latest · 4 hours of coverage · 2 countries

The ⁠vaccine, called galinpepimut-S ⁠or GPS, was tested in patients with acute ​myeloid ‌leukaemia, a fast-growing cancer of the blood and bone marrow (The Hindu Health)

Coverage, in order

  1. first The Hindu Health India mainstream study
    Sellas’ cancer vaccine extends survival in blood cancer trial, company says

    The ⁠vaccine, called galinpepimut-S ⁠or GPS, was tested in patients with acute ​myeloid ‌leukaemia, a fast-growing cancer of the blood and bone marrow

  2. ThePrint Health India indie study randomized trial
    ‘Off-the-shelf’ cancer vaccine extends survival of leukemia patients by 9 months, finds Phase 3 trial

    Patients who received vaccine had median overall survival of 24 months, compared against 14.7 months among those given best treatment. It also reduced the risk of death by 41%.

  3. TrialSite News obscure study randomized trial
    SELLAS Cancer Vaccine Cuts Death Hazard 41% in Phase 3 AML Trial: A Genuine Breakthrough or a Biotech Victory Lap?

    SELLAS Cancer Vaccine Cuts Death Hazard 41% in Phase 3 AML Trial: A Genuine Breakthrough or a Biotech Victory Lap?

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.